factor-I (IGF-I). Both are used diagnostically; IGF-I is used to monitor the effects of GH replacement in GH deficiency (GHD), and both GH and IGF-I are used in the diagnosis and management of acromegaly. While serum IGF-I level is used as a surrogate
Gudmundur Johannsson, Martin Bidlingmaier, Beverly M K Biller, Margaret Boguszewski, Felipe F Casanueva, Philippe Chanson, Peter E Clayton, Catherine S Choong, David Clemmons, Mehul Dattani, Jan Frystyk, Ken Ho, Andrew R Hoffman, Reiko Horikawa, Anders Juul, John J Kopchick, Xiaoping Luo, Sebastian Neggers, Irene Netchine, Daniel S Olsson, Sally Radovick, Ron Rosenfeld, Richard J Ross, Katharina Schilbach, Paulo Solberg, Christian Strasburger, Peter Trainer, Kevin C J Yuen, Kerstin Wickstrom, Jens O L Jorgensen and on behalf of the Growth Hormone Research Society
Urszula Smyczyńska, Joanna Smyczyńska, Maciej Hilczer, Renata Stawerska, Ryszard Tadeusiewicz and Andrzej Lewiński
), in some of them also concentrations of IGF-I ( 7 , 8 , 9 , 13 ) and IGFBP-3 ( 7 , 9 ) have been processed. The most frequently used method of deriving models of GH therapy outcomes has been multiple linear regression (MLR) ( 6 , 7 , 10 , 11
M Krause, H Frederiksen, K Sundberg, F S Jørgensen, L N Jensen, P Nørgaard, C Jørgensen, P Ertberg, J H Petersen, U Feldt-Rasmussen, A Juul, K T Drzewiecki, N E Skakkebaek and A M Andersson
factor I (IGF-I) and its major binding protein: insulin-like growth factor-binding protein-3 (IGFBP3). IGF-I and IGFBP3 were both measured by a chemiluminescence immunoassay on the IDS-iSYS automated platform (Immuno Diagnostic Systems, IDS) at the
Werner F Blum, Abdullah Alherbish, Afaf Alsagheir, Ahmed El Awwa, Walid Kaplan, Ekaterina Koledova and Martin O Savage
Introduction The growth hormone (GH)–insulin-like growth factor (IGF)-I axis is the principle endocrine system regulating linear growth in children ( 1 ). Linked to the nutritional status of the individual, GH is a potent stimulator of IGF-I
Alessandro Ciresi, Stefano Radellini, Valentina Guarnotta, Maria Grazia Mineo and Carla Giordano
one of the most influential regulators of growth hormone (GH) secretion and action, with different mechanisms ( 2 ). Androgens and estrogens exert opposite endocrine-mediated effects on insulin-like growth factor (IGF)-I production and metabolic
Juliane Léger, Anne Fjellestad-Paulsen, Anne Bargiacchi, Catherine Doyen, Emmanuel Ecosse, Jean-Claude Carel and Marie-France Le Heuzey
involving the growth hormone (GH)-insulin-like growth factor-I (IGF-I) axis, thyroid function, hypercortisolemia, hypogonadotropic hypogonadism and the levels of several adipokines and gut peptides, such as ghrelin and peptide YY ( 2 ). The
Elena Valassi, Natalia García-Giralt, Jorge Malouf, Iris Crespo, Jaume Llauger, Adolfo Díez-Pérez and Susan M Webb
secondary hypogonadism. Because all of them were on stable testosterone replacement for more than 1 year, they were considered eugonadal. Nine women had regular menses and seven were postmenopausal. None of the patients had GH deficiency, diagnosed when IGF-I
Ananda A Santana-Ribeiro, Giulliani A Moreira-Brasileiro, Manuel H Aguiar-Oliveira, Roberto Salvatori, Victor Carvalho, Claudia K Alvim-Pereira, Carlos R Araújo-Daniel, Julia G Reis-Costa, Alana L Andrade-Guimarães, Alecia Ao Santos, Edgard R Vieira and Miburge B Gois-Junior
Objectives: Walking and postural balance are extremely important to obtain food and to work. Both are critical for quality of life and ability to survive. While walking reflects musculoskeletal and cardiopulmonary systems, postural balance depends on body size, muscle tone, visual, vestibular, and nervous systems. Since GH and IGF-I act on all these systems, we decided to study those parameters in a cohort of individuals with severe short stature due to untreated isolated GH deficiency (IGHD) caused by a mutation in the GHRH receptor gene. These IGHD subjects despite reduction in muscle mass, are very active and have normal longevity.
Methods: In a cross-sectional study we assessed walking (by a 6-minute walk test), postural balance (by force platform) and falls risk (by the timed Up and Go test) in 31 IGHD and 40 matched health controls.
Results: The percentage of the walked measured distance in relation to the predicted one was similar in groups, but higher in IGHD, when corrected by the leg length. Absolute postural balance data showed similar velocity of unipodal support in the two groups, and better values, with open and closed eyes and unipodal support, in IGHD. Most differences in postural balance became non-significant when corrected for height and lower limb length. The time in timed up and go test was higher in IGHD, but still below of the cut off value falls risk.
Conclusion: IGHD subjects showed normal or better walking and similar postural balance, without increase in falls risk.
Robert Rapaport, Peter A Lee, Judith L Ross, Paul Saenger, Vlady Ostrow and Giuseppe Piccoli
(eg, HSDS, age, insulin-like growth factor 1 (IGF-I) SDS) on changes in HSDS in response to GH therapy over time ( 12 , 13 ). The analysis described here evaluated growth outcomes (HSDS, IGF-I SDS and BMI SDS), bone age per chronological age (BA
K L Gatford, G K Heinemann, S D Thompson, J V Zhang, S Buckberry, J A Owens, G A Dekker, C T Roberts and on behalf of the SCOPE Consortium
Khosravi MJ Diamandis A van Doorn J Juul A . Insulin-like growth factors (IGF-I, free IGF-I, and IGF-II) and insulin-like growth factor binding proteins (IGFBP-2, IGFBP-3, IGFBP-6, and ALS) in blood circulation . Journal of Clinical Laboratory